We are live on ! Find out more

iSpecimen

ISPC

Market cap $1.66M

0.6587 USD

-0.0378

5.43%

At close Updated Nov 13, 4:00 PM EST

Pre-market

After hours

0.6589

+0.0002

0.03%

1 day

-5.43%

5 days

-17.77%

1 month

-39.01%

3 months

-71.36%

6 months

-84.35%

Year to date

-94.24%

1 year

-97.34%

5 years

-99.98%

10 years

-99.99%

About: iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.

Employees: 7

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products

New Agentic AI tools for protein discovery and disease trend prediction take iSpecimen beyond its biospecimen marketplace Woburn, Massachusetts--(Newsfile Corp. - November 5, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace connecting scientists who need biospecimens for medical research with a network of healthcare specimen providers, today announced that it completed, on November 2, 2026, the acquisition of two artificial intelligence products from Foldlab AI Ltd. ("Foldlab"), a British Columbia company: an AI agent that identifies disease-associated proteins and an AI model that predicts and monitors disease trends.

iSpecimen Expands Into AI-Powered Drug Discovery and Disease Trend Monitoring With Acquisition of Foldlab AI Products

iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent

Woburn, Massachusetts--(Newsfile Corp. - October 29, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), a provider of human biospecimens, today announced expanded access to fully consented, prospectively collected healthy donor whole blood through an existing collection partner. The expanded capability gives researchers a streamlined option for sourcing whole blood collected specifically for research.

iSpecimen Offers Next-Day Healthy Donor Blood and Launches Development of AI Agent

iSpecimen Supports Hospital Validation of New Chemistry Analyzer

Company coordinates collection of more than 1,700 human specimens to support new laboratory testing capabilities Woburn, Massachusetts--(Newsfile Corp. - September 29, 2026) - iSpecimen, a provider of human biospecimens, is supporting a hospital laboratory in the validation of a new chemistry analyzer for clinical use. For the project, iSpecimen identified a healthcare system already using the same analyzer and is coordinating the collection of more than 1,700 serum, plasma, cerebrospinal fluid (CSF), and urine specimens for use in the hospital's validation process.

iSpecimen Supports Hospital Validation of New Chemistry Analyzer

iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

Woburn, MA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- iSpecimen, a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the samples shipped within three weeks of receiving the purchase order. The project involved the coordination of large-scale biospecimen sourcing and fulfillment on an accelerated timeline.

iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

WOBURN, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced public offering of an aggregate of 996,231 shares of the Company's common stock and pre-funded warrants to purchase up to an aggregate of 2,849,923 shares of common stock, for an aggregate purchase price of approximately $5.0 million. The Company intends to use the proceeds of the offering for repayment of outstanding liabilities, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services. The remainder of the proceeds will be used for working capital purposes.

iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants

E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen

Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025 Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025

E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen

E.F. Hutton & Co. Serves as Exclusive Placement Agent on iSpecimen Inc. $2.5 Million Private Placement

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the exclusive placement agent in connection with a $2.5 million private placement for iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers.

E.F. Hutton & Co. Serves as Exclusive Placement Agent on iSpecimen Inc. $2.5 Million Private Placement

iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement

May 8, 2026 WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it has priced a private placement with accredited investors for aggregate gross proceeds of approximately $2.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement

iSpecimen Announces 1-for-40 Reverse Stock Split

Woburn, Massachusetts--(Newsfile Corp. - April 24, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, as well as any shares of common stock held by the Company in treasury, at a ratio of 1-for-40. The reverse stock split will become effective at 4:30 p.m.

iSpecimen Announces 1-for-40 Reverse Stock Split

iSpecimen Achieves 85% Reduction in Human Biospecimen Shipping Time

Woburn, Massachusetts--(Newsfile Corp. - April 9, 2026) - iSpecimen (NASDAQ: ISPC), an online marketplace for human biospecimens, has implemented a streamlined shipping model that enables direct shipment of biospecimens from supplier sites to customers, both domestically and internationally. By reducing reliance on centralized hub processing, the new model simplifies logistics and eliminates multi-step routing.

iSpecimen Achieves 85% Reduction in Human Biospecimen Shipping Time

See News Rankings

Price charts implemented using Lightweight Charts™